Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Published Time:
2025-01-22 17:49
Source:
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
Dr. Gong Yanchun, Co-founder and CEO, stated: "Jiangsu Vcare has always adhered to the strategic layout of dual-wheel drive and coordinated development of its two core businesses: independent research and development of innovative drugs, and full-industry-chain CRO/CDMO services for pharmaceuticals.Three self-developed drug candidates have now entered confirmatory clinical studies, while our CRO/CDMO business continues rapid expansion with increasingly diversified service models. Our forward-looking strategic planning positions us to further solidify core competitiveness. With strong support from investors , we will break new ground, navigate market cycles, and achieve sustainable high-quality development."
Previous Page
Related News
27
2017
/
03
Vice Chairman of Political Consultative Conference of Wenzhou Ouhai District Visited Jiangsu Vcare
The delegation of Political Consultative Conference of Wenzhou Ouhai District, accompanied by vice chairman of Political Consultative Conference of Pukou Economic Development Zone visited Jiangsu Vcare Pharmaceutical Technology Co., Ltd. on the afternoon of March 27, 2017. Yongqiang Liu, the general manager of Jiangsu Vcare received the delegation. Mr. Liu introduced the company's development history and R&D progress. He focused on the progress of phase II clinical trials and the future market prospect of innovative drug Vicagrel. The delegation highly recognized Vcare's advanced equipment and facilities, harmonious human environment and comprehensive research and development capabilities.
View Details
14
2017
/
03
Jiangsu Vcare Held “Firefighting and First Aid” Training
Jiangsu Vcare invited Lei Wang, a special instructor of Nanjing Anqu Fire Education Center to give a “Firefighting and First Aid” course to new employees on March 14, 2017 and 26 new employees participated in the training. Mr. Wang collected a large number of fire cases and carefully analyzed the causes of these fires. He taught everyone how to deal with fires. His explanations made everyone fully aware of the importance and urgency of fire safety. At the same time, everyone had a better understanding of various fire extinguishers and their instructions.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn